Dr. Saji Eapen, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Years since graduation
- 35
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 489
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
TN license MD41548
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Fort Sanders Regional Medical Center Knoxville, TN
- Physicians Regional Medical Center Powell, TN
- Morristown Hamblen Hospital Association Morristown, TN
- Tennova Healthcare - Newport Medical Center Newport, TN
- Lafollette Medical Center La Follette, TN
Medical groups
- Tennessee Cancer Specialists PLLC (67 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 489
- Services billed
- 129,222
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 22,090 | 16 |
| Injection, denosumab, 1 mg | 8,100 | 44 |
| Injection, ferric derisomaltose, 10 mg | 5,300 | 37 |
| Injection, dexamethasone sodium phosphate, 1 mg | 2,140 | 29 |
| Injection, ondansetron hydrochloride, per 1 mg | 1,408 | 19 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 1,101 | 353 |
| Insertion of needle into vein for collection of blood sample | 982 | 359 |
| Blood test, comprehensive group of blood chemicals | 911 | 344 |
| Established patient office or other outpatient visit, 30-39 minutes | 440 | 186 |
| Established patient office or other outpatient visit, 20-29 minutes | 378 | 243 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Imbruvica (ibrutinib) | 44 |
| Revlimid (lenalidomide) | 41 |
| Ondansetron Hcl Other prescribers in Knoxville, TN | 40 |
| Calquence (acalabrutinib maleate) | 30 |
| Ibrance (palbociclib) | 24 |
| Lenalidomide | 21 |
| Levofloxacin Other prescribers in Knoxville, TN | 20 |
| Prednisone Other prescribers in Knoxville, TN | 19 |
| Brukinsa (zanubrutinib) | 16 |
| Hydroxyurea Other prescribers in Knoxville, TN | 16 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 31 companies reported 62 payments worth $1,544 in total to this clinician.
| AbbVie Inc. | $150 |
|---|---|
| Iovance Biotherapeutics, Inc. | $145 |
| Novartis Pharmaceuticals Corporation | $127 |
| Pfizer Inc. | $112 |
| Gilead Sciences, Inc. | $108 |
| AstraZeneca Pharmaceuticals LP | $92.60 |
| Jazz Pharmaceuticals Inc. | $89.99 |
| Celgene Corporation | $64.28 |
| Food and Beverage | $1,434 |
|---|---|
| Education | $110 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Jazz Pharmaceuticals Inc. Aug 6, 2025 | Education XYWAV · NEUROLOGY · in-kind | $89.99 |
| Aveo Pharmaceuticals, Inc. Mar 3, 2025 | Education FOTIVDA · Oncology · in-kind | $20.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $24,513 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Genzyme Corporation · Active, not recruiting · NCT06356571
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.